pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA) · news · pharmadog
← back to TEVA PHARMACEUTICAL INDUSTRIES LTD
News mentioning $TEVA
52
stories
2d
Foghorn cuts 40% of workforce
biospace
3d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
24d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 2, 26
Teva says gluten challenge study succeeds in celiac disease
endpoints
Sep 2, 26
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
biopharma dive
Sep 2, 26
Teva autoimmune antibody notches ph. 2 win in celiac disease
fiercebiotech
Sep 1, 26
Mid-cap biotechs join Trump’s latest round of drug pricing deals
biopharma dive
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 31, 26
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
Aug 31, 26
STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more
stat
Aug 28, 26
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
biospace
Aug 28, 26
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
endpoints
Aug 28, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
fiercebiotech
Aug 27, 26
STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
stat
Aug 26, 26
STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more
stat
Aug 25, 26
STAT+: Sword Health to acquire Headspace, according to filing
stat
Aug 25, 26
Pennsylvania reports first 2 measles deaths in the U.S. this year, both people unvaccinated
stat
Aug 25, 26
STAT+: Turkish antitrust authorities probe Teva for allegedly gaming the patent system, disparaging rival drugs
stat
Aug 25, 26
Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves
raps
Aug 19, 26
Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom
endpoints
Aug 17, 26
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
Aug 17, 26
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
Aug 13, 26
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
Aug 6, 26
Judge signs off on Teva's $35M settlement over delayed inhaler generics
endpoints
Aug 5, 26
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
← prev
page 1 of 2
next →
